Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this clinical trial is to learn about the good and the bad effects of all
trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced
colorectal patients.
Participants will be treated with the following combination of these drugs:
1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on
day 1 of a cycle.
2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes
every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.
3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes
every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.